Rahul Gosain, MD

Safety Profile Considerations for Enfortumab Vedotin Plus Pembrolizumab

Following a discussion centered on the EV-302 study, Thomas Powles, MBBS, MRCP, MD, and the Oncology Brothers discuss the role of circulating tumor DNA in urothelial cancer.

Rohit Gosain, MD;Rahul Gosain, MD;Thomas Powles, MD, MBBS, MRCP

The Role of Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

A comprehensive discussion on treatment-related adverse events seen in patients receiving enfortumab vedotin and pembrolizumab.

Rohit Gosain, MD;Rahul Gosain, MD;Thomas Powles, MD, MBBS, MRCP

EV-302 Study Design and Results

The Oncology Brothers are joined by Thomas Powles, MBBS, MRCP, MD, to discuss the role of enfortumab vedotin plus pembrolizumab in the bladder cancer treatment landscape.

Rohit Gosain, MD;Rahul Gosain, MD;Thomas Powles, MD, MBBS, MRCP

Key Takeaways on Zanubrutinib Data

Thomas Powles, MBBS, MRCP, MD, joins the Oncology Brothers to discuss the study design and results of the EV-302 trial investigating enfortumab vedotin plus pembrolizumab in untreated advanced urothelial carcinoma.

Rahul Gosain, MD; Rohit Gosain, MD; and Mazyar Shadman, MD, MPH, presenting slides

Rahul Gosain, MD;Rohit Gosain, MD;Mazyar Shadman, MD, MPH

Zanubrutinib Safety Profile in CLL

Following a discussion on zanubrutinib that highlighted clinical trial data, treatment practices, and adverse event considerations, the Oncology Brothers offer concluding thoughts.

Rahul Gosain, MD;Rohit Gosain, MD;Mazyar Shadman, MD, MPH

Efficacy of Zanubrutinib vs Acalabrutinib in R/R CLL: A Matching-Adjusted Indirect Comparison

Mazyar Shadman, MD, MPH, provides clinical insights on adverse events seen with zanubrutinib in patients with chronic lymphocytic leukemia.

Rahul Gosain, MD;Rohit Gosain, MD;Mazyar Shadman, MD, MPH

ALPINE: Zanubrutinib or Ibrutinib in Relapsed/Refractory CLL

A comprehensive discussion on a matching-adjusted indirect comparison study investigating the efficacy of zanubrutinib vs acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Rahul Gosain, MD;Rohit Gosain, MD;Mazyar Shadman, MD, MPH

SEQUOIA: Zanubrutinib vs BR in First-Line CLL/SLL

Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Mazyar Shadman, MD, MPH, to discuss the ALPINE study looking at zanubrutinib vs ibrutinib in relapsed or refractory CLL.

Rahul Gosain, MD;Rohit Gosain, MD;Mazyar Shadman, MD, MPH

Key Takeaways from CAPItello-291 in HR+ Breast Cancer

Mazyar Shadman, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD; and Rahul Gosain, MD, to discuss the SEQUOIA trial investigating zanubrutinib vs bendamustine-rituximab in first-line CLL/SLL.

Rohit Gosain, MD; Rahul Gosain, MD; and Hope Rugo, MD, presenting slides

Adverse Event Data from CAPItello-291 in HR+ Breast Cancer

Following a comprehensive review of CAPItello-291, Rohit Gosain, MD, and Rahul Gosain, MD, provide closing thoughts on key takeaways.

Key Data from CAPItello-291 in HR+ Breast Cancer

Focusing on the safety profile, the Oncology Brothers and Hope Rugo, MD, review safety data from CAPItello-291 and discuss adverse event management practices for patients with breast cancer.

Biomarker Testing and Prevalence of AKT1/PIK3CA/PTEN Mutations in Breast Cancer

Hope Rugo, MD, reviews key data from CAPItello-291 on capivasertib in patients with HR+ breast cancer, highlighting progression-free survival and overall survival.

Rationale and Study Design of CAPItello-291 in HR+ Advanced Breast Cancer

Medical oncologists provide insights on biomarker testing and the prevalence of AKT1, PIK3CA, and PTEN mutations in breast cancer.

Overall Survival Update for KEYNOTE-564 in Renal Cell Carcinoma

Hope Rugo, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the rationale and study design for CAPItello-291 in HR+ advanced breast cancer.

Rohit Gosain, MD; Rahul Gosain, MD; and Tian Zhang, MD, presenting slides

AMBASSADOR: Adjuvant Pembrolizumab in Muscle-Invasive Urothelial Carcinoma

Tian Zhang, MD, and the Oncology Brothers offer comprehensive insights on the overall survival update for KEYNOTE-564 in renal cell carcinoma.

BRCAAway: Novel Hormonal Therapies With PARP inhibitors in mCRPC

A review of interim findings from the AMBASSADOR study looking at adjuvant pembrolizumab in patients with muscle-invasive urothelial carcinoma.

CONTACT-02: Cabozantinib Plus Atezolizumab in mCRPC

Tian Zhang, MD, and the Oncology Brothers discuss the BRCAAway trial, which is investigating abiraterone, olaparib, or the combination in patients with metastatic castration-resistant prostate cancer.

Key Takeaways from 2024 ASCO GI Cancers Symposium

Following ASCO GU 2024, Tian Zhang, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from CONTACT-02 investigating cabozantinib plus atezolizumab in metastatic castration-resistant prostate cancer.

Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides

Rohit Gosain, MD;Rahul Gosain, MD;Pamela L. Kunz, MD

The Role of ctDNA in Colorectal Cancer

Following their review of recent data from the 2024 ASCO GI Cancers Symposium, the Oncology Brothers discuss their key takeaways.

Rohit Gosain, MD;Rahul Gosain, MD;Pamela L. Kunz, MD

NETTER-2: Lu-177 Dotatate for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors

Medical oncologists offer comprehensive insights on the role of circulating tumor DNA in the treatment of patients with colorectal cancer.

Rohit Gosain, MD;Rahul Gosain, MD;Pamela L. Kunz, MD

EMERALD-1: Durvalumab/Bevacizumab Plus TACE in Unresectable HCC

Clinical insights on the recent data from the NETTER-2 trial looking at Lu-177 Dotatate in patients with advanced gastroenteropancreatic neuroendocrine tumors.

Rohit Gosain, MD;Rahul Gosain, MD;Pamela L. Kunz, MD

CheckMate 8HW: Nivolumab Plus Ipilimumab in MSI-High/dMMR Metastatic Colorectal Cancer

Pamela L. Kunz, MD, and the Oncology Brothers provide insights on the EMERALD-1 trial looking at durvalumab and bevacizumab plus TACE in patients with unresectable, embolization-eligible hepatocellular carcinoma.

Rohit Gosain, MD;Rahul Gosain, MD;Pamela L. Kunz, MD

Key Takeaways from ASH 2023 in Myelofibrosis and AML

Following ASCO GI 2024, Pamela L. Kunz, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from the CheckMate 8HW study investigating nivolumab plus ipilimumab in MSI-high/mismatch repair deficient metastatic colorectal cancer.

Rohit Gosain, MD; Rahul Gosain, MD; and Uma Borate, MBBS, presenting slides

Revumenib for Patients With Acute Myeloid Leukemia

Following their review of updates from clinical trials presented at ASH 2023, the Oncology Brothers provide their key takeaways on recent data in myelofibrosis and acute myeloid leukemia.

MANIFEST-2: Pelabresib plus Ruxolitinib in JAK Inhibitor–Naïve Myelofibrosis

Medical oncologists discuss the results from the SAVE and AUGMENT-101 clinical trials investigating revumenib in patients with acute myeloid leukemia.

TRANSFORM-1: Navitoclax and Ruxolitinib in Untreated Myelofibrosis

Uma Borate, MBBS, and the Oncology Brothers provide insights gleaned from the MANIFEST-2 study, a phase 3, randomized, double-blind study on pelabresib plus ruxolitinib for JAK inhibitor treatment–naïve patients with myelofibrosis.